These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis. Aalbers CJ; Bevaart L; Loiler S; de Cortie K; Wright JF; Mingozzi F; Tak PP; Vervoordeldonk MJ PLoS One; 2015; 10(6):e0130612. PubMed ID: 26107769 [TBL] [Abstract][Full Text] [Related]
23. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. van de Loo FA; van den Berg WB Rheum Dis Clin North Am; 2002 Feb; 28(1):127-49. PubMed ID: 11840694 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic gene transfer for rheumatoid arthritis. Boissier MC; Bessis N Reumatismo; 2004; 56(1 Suppl 1):51-61. PubMed ID: 15201941 [TBL] [Abstract][Full Text] [Related]
25. Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Chernajovsky Y; Feldmann M; Maini RN Br Med Bull; 1995 Apr; 51(2):503-16. PubMed ID: 7552079 [TBL] [Abstract][Full Text] [Related]
27. [Gene therapy in rheumatoid arthritis: new aspects]. Pundt N; Peters MA; Wunrau C; Pap T Dtsch Med Wochenschr; 2008 Aug; 133(34-35):1737-41. PubMed ID: 18696407 [TBL] [Abstract][Full Text] [Related]
28. Arthritis: is the cure in your genes? Herndon JH; Robbins PD; Evans CH J Bone Joint Surg Am; 1999 Feb; 81(2):152-7. PubMed ID: 10073578 [No Abstract] [Full Text] [Related]
29. Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis. Broeren MG; de Vries M; Bennink MB; Arntz OJ; Blom AB; Koenders MI; van Lent PL; van der Kraan PM; van den Berg WB; van de Loo FA Hum Gene Ther; 2016 Mar; 27(3):244-54. PubMed ID: 26711533 [TBL] [Abstract][Full Text] [Related]
30. Technology insight: gene transfer and the design of novel treatments for rheumatoid arthritis. Moritz F; Distler O; Ospelt C; Gay RE; Gay S Nat Clin Pract Rheumatol; 2006 Mar; 2(3):153-62. PubMed ID: 16932675 [TBL] [Abstract][Full Text] [Related]
31. Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5. Tas SW; Adriaansen J; Hajji N; Bakker AC; Firestein GS; Vervoordeldonk MJ; Tak PP Hum Gene Ther; 2006 Aug; 17(8):821-32. PubMed ID: 16942442 [TBL] [Abstract][Full Text] [Related]
32. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. Woods JM; Katschke KJ; Tokuhira M; Kurata H; Arai KI; Campbell PL; Koch AE J Immunol; 2000 Sep; 165(5):2755-63. PubMed ID: 10946307 [TBL] [Abstract][Full Text] [Related]
33. Selected cytokine pathways in rheumatoid arthritis. Noack M; Miossec P Semin Immunopathol; 2017 Jun; 39(4):365-383. PubMed ID: 28213794 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic targets for rheumatoid arthritis: Progress and promises. Alghasham A; Rasheed Z Autoimmunity; 2014 Mar; 47(2):77-94. PubMed ID: 24437572 [TBL] [Abstract][Full Text] [Related]
39. Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Tarner IH; Neumann E; Gay S; Fathman CG; Müller-Ladner U Autoimmun Rev; 2006 Feb; 5(2):148-52. PubMed ID: 16431349 [TBL] [Abstract][Full Text] [Related]
40. Ex vivo gene transfer in the years to come. Pap T; Gay RE; Müller-Ladner U; Gay S Arthritis Res; 2002; 4(1):10-2. PubMed ID: 11879532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]